Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-137 multiple rising doses in adult ADHD
NCT02163915Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jun 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-137 in attention deficit hyperactivity disorder (ADHD) (6 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event, Percentage of Participants Who Meet the Takeda Markedly Abnormal Criteria for Safety Laboratory Tests and 4 more. Started Jun 2014; status: terminated.
02
Drugs
TAK-137
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02163915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163915.